Advances in the Treatment of T-Cell Lymphomas: A Forum for Data and Case Discussion

Advances in the Treatment of T-Cell Lymphomas: A Forum for Data and Case Discussion

Friday, December 9, 2022 in New Orleans, LA
Lunch -- Sheraton New Orleans, 11:00 AM CT
Rhythms Ballroom


Welcome, Introduction, Baseline Assessment

  • Overview of Modern Molecular and Phenotypic Workup for T-Cell Lymphomas
    • Diagnostic workup and biomarker assessment
  • Planning Frontline Treatment for PTCL and CTCL Subtypes
    • Novel targeted agents and combination strategies
  • Improving Outcomes for Relapsed/Refractory (R/R) PTCL and CTCL Subtypes
    • Novel targeted agents and combination strategies
  • Anaplastic large cell lymphoma treatment algorithm and ongoing clinical trials

Final Thoughts and Audience Question and Answer Session


Program Director
Steven M. Horwitz, MD

Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Memorial Hospital
Professor of Medicine, Weill Cornell Medical College
New York, New York

Pamela B. Allen, MD

Assistant Professor
Department of Hematology/Oncology
Emory University, Winship Cancer Institute
The Emory Clinic
Atlanta, Georgia

Kerry J. Savage, MD, MSc

Associate Professor
Department of Medicine, Division of Medical Oncology
Medical Oncologist
Department of Medical Oncology
British Columbia Cancer Agency
Vancouver, British Columbia, Canada

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in selecting individualized treatments for patients with T-cell lymphomas.

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with T-cell lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan individualized treatment decisions in patients with T-cell lymphomas, based on assessment of molecular and phenotypic biomarkers and accurate lymphoma subclassification
  • Integrate single-agent or combination targeted therapy into management plans for patients with T-cell lymphomas
  • Evaluate the latest clinical trial data for novel agents and emerging therapeutic strategies across different T-cell lymphomas
  • Manage treatment-related adverse events through agent familiarity and robust monitoring efforts
  • Identify patients diagnosed with T-cell lymphomas who are eligible for enrollment on ongoing clinical trials


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.